News and Resources
Acutus Medical, Inc. Initiates “First-In-Man” Clinical Study of Real-Time 3D Imaging Catheter with CT/MRI Quality
San Diego, California, April 30, 2013—Acutus Medical, Inc. (ACM or Company), an emerging developer and manufacturer of medical devices designed to provide real-time 3D cardiac electrical mapping based on dipole density for the treatment of cardiac arrhythmias, announced today that it has performed its First-In-Man clinical study of its cardiac catheter to provide highest-quality real-time 3D mapping of the human heart.
The first four patient procedures were performed by Principal Investigator Professor Mattias Duytschaever, MD, at Sint-Jan Hospital in Brugge, Belgium.
We are very pleased with the progress of our First-In-Man clinical study and we look forward to the forthcoming studies for our technology in the European markets” said Randy Werneth, CEO/President. “We have the ability in a matter of seconds to generate real-time 3D images of the heart with quality equivalent to a CT or MRI.
About Acutus Medical
Since June, 2011, Acutus Medical has pioneered a new and novel approach in the minimally invasive imaging and mapping of cardiac arrhythmias.
Acutus Medical has concentrated its efforts on the developing its technology for the treatment of an aberrant arrhythmia, atrial fibrillation (AF). Acutus Medical believes that its technology may eventually play a significant role in improving the lives of countless individuals who are afflicted by AF.
This press release includes forward-looking statements regarding Acutus Medical Cardiac Imaging and Mapping Technology System. Any statement describing Acutus Medical’s goals, expectations, intentions or beliefs is a forward-looking statement and should be considered an at-risk statement, including those statements that are described as Acutus goals. Such statements are subject to certain risks and uncertainties, particularly those inherent in the process of discovering, developing and commercializing products and in the endeavor of building a business around such products. Acutus Medical’s forward-looking statements also involve assumptions that, if they never materialize or prove correct, could cause its results to differ materially from those expressed or implied by such forward-looking statements. Although Acutus Medical forward-looking statements reflect the good faith judgment of its management, these statements are based only on facts and factors currently known by Acutus Medical. As a result, you are cautioned not to rely on these forward-looking statements.
Download PDF of this press release:
PDF Press Release: Acutus Medical, Inc. Initiates “First-In-Man” Clinical Study of Real-Time 3D Imaging Catheter with CT/MRI Quality
_________________________
For More Information, please contact:
Acutus Medical
Mr. Randy Werneth
CEO / President
Acutus Medical, Inc. Announces Issuance of a New Patent on Dipole Density Mapping on Heart Walls
SAN DIEGO, CA.—Acutus Medical announced the issuance of U.S. Patent number 8,417,313 which relates to the method and device for determining and presenting surface charge and dipole density on cardiac walls.
This patent focuses on an innovative method in cardiac electrophysiology and demonstrates Acutus Medical’s leadership in developing novel technologies for mapping the true electrical source of the heart wall’s electrical activation.” Randy Werneth, President and Chief Executive Officer stated. “This is another example of the importance of our intellectual property strategy as we continue to actively protect the enhanced mapping technologies. Over the past eighteen months, Acutus Medical has filed over 25 patent inventions.
This is the first patent issued relating to Acutus Medical’s new imaging and mapping technology.
About Acutus Medical
Since June, 2011, Acutus Medical has pioneered a new and novel approach in the minimally invasive imaging and mapping of cardiac arrhythmias.
Acutus Medical has concentrated its efforts on developing its technology for the treatment of an aberrant arrhythmia, atrial fibrillation (AF). AF is an uncontrollable, rapid, heartbeat that results in a significant decline in the quality of life and may lead to serious complications such as stroke or heart failure. Globally, in excess of 10 million people are afflicted with AF. Pharmacological therapy is the most common current treatment option, but it is expensive, often inadequate, is palliative in nature, and does not cure AF.
Acutus Medical believes that its technology may eventually play a significant role in improving the lives of countless individuals who are afflicted by AF.
This press release includes forward-looking statements regarding Acutus Medical Cardiac Imaging and Mapping Technology System. Any statement describing Acutus Medical’s goals, expectations, intentions or beliefs is a forward-looking statement and should be considered an at-risk statement, including those statements that are described as Acutus goals. Such statements are subject to certain risks and uncertainties, particularly those inherent in the process of discovering, developing and commercializing products and in the endeavor of building a business around such products. Acutus Medical’s forward-looking statements also involve assumptions that, if they never materialize or prove correct, could cause its results to differ materially from those expressed or implied by such forward-looking statements. Although Acutus Medical forward-looking statements reflect the good faith judgment of its management, these statements are based only on facts and factors currently known by Acutus Medical. As a result, you are cautioned not to rely on these forward-looking statements.
Download PDF of this press release:
PDF Press Release: Acutus Medical, Inc. Announces Issuance of a New Patent on Dipole Density Mapping on Heart Walls
_________________________
For More Information, please contact:
Acutus Medical
Mr. Randy Werneth
CEO / President
Device Companies Follow New Map To Atrial Fibrillation
Three years ago, the FDA approved Johnson & Johnson’s thermocool, the first in a series of ablation catheters specifically designed to halt atrial fibrillation. Despite these advances, the long-term success rates of catheter ablation procedures remain low, opening the door for start-ups to devise new approaches.
By Mary Stuart
Advent Life Sciences Invests in Acutus Medical and Acutus Medical Expands Senior Management Team
—Funds and team growth for developing a breakthrough medical system for mapping of atrial fibrillation— 20th January 2012, London: – Advent Life Sciences announced it has invested $2.2 million in Acutus Medical, a medical technology company based in San Diego and Zurich, as part of a Series A of $5.4 million which includes previously announced…
Electrophysiology of Living Organs From First Principles
Gϋnter Scharf Institut fϋr Theoretische Physik, Universitӓt Zϋrich, Winterthurerstr. 190 , CH-8057 Zϋrich, Switzerland Lam Dang and Christoph Scharf Cardiac Electrophysiology, Clinic im Park, Seestrasse 220, CH-8027 Zϋrich, Switzerland View and Download Paper: http://arxiv.org/PS_cache/arxiv/pdf/1006/1006.3453v1.pdf
Index Ventures Invests in Acutus Medical
New medical technology company focused on developing a breakthrough device for real time mapping of Atrial Fibrillation 8th August 2011, San Diego, USA: – Index Ventures, together with private investors, has invested an initial funding of $1 million in Acutus Medical, a newly founded medical technology company based in San Diego. The Company is developing…